GSK Stock Recent News

Sleeper stocks to buy – based on Nasdaq.com's glossary – represent securities that offer significant price appreciation potential once its fundamentals have been recognized. That could cover a lot of enterprises so I decided to narrow down the list.

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We have narrowed our search to five low-beta stocks with a solid dividend yield. These are: TAP, TSN, TM, GSK and BAH.

GSK PLC (LSE:GSK, NYSE:GSK) boss Emma Walmsley saw her overall pay rise 51% to around £13 million in 2023 after she received a large hike in performance-related bonuses. Some £11 million of the pay came from performance bonuses and awards after the pharma giant beat estimates in the fourth quarter of 2023 - the first full financial year since it spun off Haleon.

In the most recent trading session, GSK (GSK) closed at $41.90, indicating a -1.04% shift from the previous trading day.

Zacks.com users have recently been watching Glaxo (GSK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

GSK plc is a multinational “big pharma” and long-time leader in the vaccine, HIV, and respiratory disease areas. Shingrix and RSV vaccine sales in 2023 exceeded expectations and appear to show no sign of slowing down. GSK's franchise only faces minor patent cliffs over the next 5-10 years, supporting its long-term growth plan.

A hedge fund has bought a 5% stake in the U.K.'s largest commercial television broadcaster ITV, as the broadcaster struggles against a slump in the advertising market that has pummeled its share price in recent years.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.